South Korean endoscopic surgical robot developer EndoRobotics has formally initiated its public listing process by naming Mirae Asset Securities as the preferred lead underwriter for its planned initial public offering. The company, led by co-CEOs Hong Dae-hee and Kim Byung-gon, is targeting a listing in the second half of 2028. This selection marks a key milestone in the company’s transition from a research-driven startup to a publicly traded medical device firm.
IPO Preparation and Underwriter Selection
The final underwriting agreement will be concluded after further discussions with Mirae Asset Securities, which was selected as the preferred lead manager. Following this step, due diligence, valuation enhancement strategies, and listing preparations will proceed under a structured timeline. EndoRobotics expects these efforts to support its target of completing a public listing in the second half of 2028.
Flexible Robotic Platform and Regulatory Milestones
The underlying technology was developed from 2012 through a research program supported by the Ministry of Science and ICT and the National Research Foundation of Korea. It was transferred from Korea University to form the basis of EndoRobotics. This academic and government-backed origin has shaped the company’s focus on flexible, non-invasive surgical robotics.
Its flagship system, ROBOPERA, is designed to enter the body without external incisions by bending flexibly through natural pathways. The platform uses an add-on robotic arm that can be attached to most existing endoscopic equipment, which the company regards as a core competitive advantage. A dual control arrangement allows an operator and an assistant to manipulate components independently.
The system supports gastrointestinal endoscopy and endoscopic submucosal dissection for removing early cancerous lesions without abdominal incisions. ROBOPERA received 510(k) clearance from the United States Food and Drug Administration under the product code NAY for robotically controlled surgical systems. EndoRobotics describes this as an important regulatory milestone and is now pursuing CE certification in Europe and approval in Japan.
Global Commercial Partnership and Investor Backing
In May 2025, EndoRobotics signed an exclusive global distribution agreement with Olympus, the world’s largest endoscopy company. Olympus plans to integrate the robotic-assisted endoscopic technology into its therapeutic endoscopy portfolio and promote advanced procedures such as endoscopic submucosal dissection worldwide. The relationship was reinforced in the fourth quarter of 2025 when Olympus participated as a strategic investor in the Series C round.
The Series C round also attracted Premier Partners, Mirae Asset Venture Investment, Mirae Asset Capital, and KNet Investment Partners. Their participation highlights institutional confidence in the company’s commercial and regulatory progress. The capital injection is expected to help fund expansion as EndoRobotics prepares for its public offering and broader market entry.
Strategic Outlook
Co-CEO Kim Byung-gon said the company’s commitment to market feedback during development has driven stronger commercialization outcomes. He added that EndoRobotics intends to use a successful IPO as a foundation to become a global surgical robot company serving the internal medicine market worldwide. The leadership sees the listing plan as a step toward expanding its commercial footprint beyond current regulatory and distribution milestones.
EndoRobotics is entering a critical phase in its corporate evolution, with its IPO preparations now supported by a major domestic securities firm and a global distribution partner. The company’s regulatory achievements and commercial agreement with Olympus provide a foundation for its public market ambitions. As it moves toward a targeted 2028 listing, the medical robot developer will aim to convert its early technical and strategic momentum into long-term market leadership.